AbbVie Inc. is 277.9x more valuable than UroGen Pharma Ltd. by market capitalization ($402.35 B vs $1.45 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | URGN | ABBV |
|---|---|---|
| Market cap | $1.45 B | $402.35 B |
| US-listed rank | #2374 | #31 |
| Revenue (latest FY) | $109.79M | $61.16B |
| Net income (latest FY) | -$153.49M | $4.23B |
| Net margin | -139.8% | 6.9% |
| P/E (trailing FY) | - | 95.2 |
| SEC filings | 549 | 1,008 |
AbbVie Inc. is 277.9x more valuable than UroGen Pharma Ltd. by market capitalization ($402.35 B vs $1.45 B).
In their latest fiscal years, UroGen Pharma Ltd. reported $109.79M in revenue while AbbVie Inc. reported $61.16B.
Full pages: UroGen Pharma Ltd. and AbbVie Inc., or browse the full rankings.